Diverse roles of metformin during peri-implantation development: Revisiting novel molecular mechanisms underlying clinical implications

Stem Cells and Development

Volumn 22, Issue 22, 2013, Pages 2927-2934

  Banerjee, Poulomi ^a   Bhonde, Ramesh R ^a   Pal, Rajarshi ^a,b  

^a Manipal Academy of Higher Education   (India)

^b MANIPAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BUFORMIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; PHENFORMIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR;

BLASTOCYST; CELL STRESS; DIABETES MELLITUS; EMBRYO CELL; EMBRYONIC STEM CELL; ENDOMETRIUM CELL; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GROWTH, DEVELOPMENT AND AGING; HIGH RISK PREGNANCY; HUMAN; HYPOXIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALNUTRITION; MOLECULAR DYNAMICS; NIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREGNANCY; PREGNANCY TERMINATION; PREIMPLANTATION EMBRYO; PRIORITY JOURNAL; REVIEW; STRESS; TROPHOBLAST;

ABORTION, SPONTANEOUS; AMP-ACTIVATED PROTEIN KINASES; EMBRYO IMPLANTATION; EMBRYONIC STEM CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN; METFORMIN; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84888043003     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0171     Document Type: Review

References (51)

1. Radziuk J, Z Zhang, N Wiernsperger and S Pye. (1997). Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 46:1406-1413.
2. Cusi K and RA DeFronzo. (1998). Metformin: a review of its metabolic effects. Diabetes 6:89-131.
3. Hundal HS, T Ramlal, R Reyes, LA Leiter and A Klip. (1992). Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 131: 1165-1173.
4. Libby G, LA Donnelly, PT Donnan, DR Alessi, AD Morris and JMM Evans. (2009). New users of metformin are at low risk of incident cancer A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
5. Kahn BB, T Alquier, D Carling and DG Hardie. (2005). AMP activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25.
6. Stein SC, A Woods, NA Jones, MD Davison and D Carling. (2000). The regulation of AMP activated protein kinase by phosphorylation. Biochem J 345:437-443.
7. Glueck CJ, H Phillips, D Cameron, LS Smith and P Wang. (2001). Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46-52.
8. Glueck CJ, P Wang, S Kobayashi, H Phillips and LS Smith. (2002). Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77:520-525.
9. Chen J and SM Downs. (2008). AMP activated protein kinase is involved in hormone induced mouse oocyte meiotic maturation in vitro. Dev Biol 313:47-57.
10. LaRosa C and SM Downs. (2006). Stress stimulates AMPactivated protein kinase and meiotic resumption in mouse oocytes. Biol Reprod 74:585-592.
11. Tosca L, C Chabrolle and J Dupont. (2008). AMPK: a link between metabolism and reproduction. Med Sci (Paris) 24:297-300.
12. Galuska D, J Zierath, A Thorne, T Sonnenfeld and HW Henriksson. (1991). Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle. Diabetes Metab 17:159-163.
13. Abbasi F, V Kamath, AA Rizvi, M Carantoni, YD Chen and GM Reaven. (1997). Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients: evidence for a central role of adipose tissue. Diabetes Care 20:1863-1869.
14. Reuben JS, M Kosmatka, N Bardeesy, RL Hurley, LA Witters, RA DePinho and LC Cantley. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101:3329-3335.
15. Cufí S, AV Martin, CO Ferraros, BM Castillo, J Joven and J Menendez. (2010). Metformin against TGFb-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9: 4461-4468.
16. Martin AV, O Ferraros, S Cufi, D Barco, SM Castillo and BJA Menendez. (2010). Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9:3807-3814.
17. Zhuang Y and WK Miskimins. (2008). Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip. J Mol Signal 3:18.
18. Zakikhani M, RJO Dowling and N Sonenberg. (2008). The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1:369-375.
19. Sakamoto K, O Göransson, DG Hardie and DR Alessi. (2004). Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 287:E310-E317.
20. Zou MH, SS Kirkpatrick, BJ Davis, JS Nelson, WG Wiles IV, U Schlattner, D Neumann, M Brownle, MB Freeman and MH Goldman. (2004). Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo role of mitochondrial reactive nitrogen species. J Biochem 279:43940-43951.
21. Zhou G, R Myers, Y Li, Y Chen, X Shen, JF Melody, M Wu, J Ventre, T Doebber, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174.
22. Zakikhani M, MJ Blouin, E Piura and MN Pollak. (2010). Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123:271-279.
23. Cantrell LA, C Zhou, A Mendivil, KM Malloy, PA Gehrig and VL Bae-Jum. (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116:92-98.
24. Sahra IB, K Laurent and S Giuliano. (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70:2465-2475.
25. Saeedi R, HL Parsons, RB Wambolt, K Paulson, V Sharma, JRB Dyck, RW Brownsey and F Michael. (2008). Allard metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol 294:H2497-H2506.
26. Foretz M, S Hébrard, J Leclerc, E Zarrinpashneh, M Soty, G Mithieux, K Sakamoto, F Andreelli and B Viollet. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120:2355-2369.
27. Kalender A, A Selvaraj, SY Kim, P Gulati, S Brule, B Viollet, BE Kemp, N Bardeesy, P Dennis, et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPasedependent manner. Cell Metab 11:390-401.
28. Mansouri L, Y Xie and DA Rappolee. (2012). Adaptive and pathogenic responses to stress by stem cells during development. Cell 1:1197-1224.
29. Janatpour MJ, MT McMaster, O Genbacev, Y Zhou, J Dong, JC Cross, MA Israel and SJ Fisher. (2000). Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration. Development 127:549-558.
30. Xie Y, A Awonuga, J Liu, E Rings, EE Puscheck and DA Rappolee. (2013). Stress induces AMP-activated protein kinase-dependent loss of potency factors inhibitor of differentiation 2 and caudal-related homeodomain protein 2 in early embryos and stem cells. Stem Cells Dev 22:1564-1575.
31. Zhong W, Y Xie, M Abdallah, AO Awonuga, JA Slater, L Sipahi, EE Puscheck and DA Rappolee. (2010). Cellular stress causes reversible, PRKAA1/2-, and proteasomedependent ID2 protein loss in trophoblast stem cells. Reproduction 140:921-930.
32. Chi MM-Y, AL Schlein and KH Moley. (2000). High insulin like growth factor I (IGF-1) and insulin concentrations trigger apoptosis in the mouse blastocyst via down-regulation of the IGF-1 receptor. Endocrinology 141:4784-4792.
33. Morales AV, J Serna, C Alarcon, EJ Rosa and F Pablo. (1997). Role of prepancreatic (pro) insulin and the insulin receptor in prevention of embryonic apoptosis. Endocrinology 138: 3967-3975.
34. Louden E, MM Chi and KH Moley. (2008). Crosstalk between the AMP-activated kinase and insulin signaling pathways rescues murine blastocyst cells from insulin resistance. Reproduction 136:335-344.
35. Nicholas J and A Smith. (2009). Nai̇ve and primed pluripotent states. Cell Stem Cell 4:487-491.
36. Zhang X, S Yalcin, DF Lee, TYJ Yeh, SM Lee, J Su, SK Mungamuri, P Rimmelé, M Kennedy, et al. (2011). FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 13:1092-1099.
37. Lim MA, MA Selak, Z Xiang, D Krainc, RL Neve, BC Kraemer, JL Watts and RG Kalb. (2012). Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J Neurosci 32:1123-1141.
38. Concannon CG, LP Tuffy, P Weisová, HP Bonner, D Dávila, C Bonner, MC Devocelle, A Strasser, MW Ward and HM Jochen. (2010). AMP kinase-mediated activation of the BH3- only protein Bim couples energy depletion to stress induced apoptosis. J Cell Biol 189:83-94.
39. Cavallo-Perin P, E Aluffi, P Estivi, A Bruno, Q Carta, G Pagano and G Lenti. (1989). The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6-month treatment. Riv Eur Sci Med Farmacol 11:45-49.
40. Legro RS, HX Barnhart, WD Schlaff, BR Carr, MP Diamond, SA Carson, MP Steinkampf, C Coutifaris, PG McGovern, et al. (2007). Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551-566.
41. Moll E, PMM Bossuyt, JC Korevaar, CB Lambalk and F van der Veen. (2006). Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. Hum Reprod 27:3273-3278.
42. Krikun G, G Mor, A Alvero, S Guller, F Schatz, E Sapi, M Rahman, R Caze, M Qumsiyeh and CJ Lockwood. (2004). A novel immortalised human endometrial stromal cell line with normal progestetional response. Endocrinology 145: 2291-2296.
43. Tang T, J Glanville, N Orsi, JH Barth and AH Balen. (2006). The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21:1416-1425.
44. Stadtmauer LA, SK Toma, RM Riehl and LM Talbert. (2001). Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 75:505-509.
45. Glueck CJ, N Goldenberg, P Wang, M Loftspring and A Sherman. (2004). Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19:510-521.
46. Stumvol M, N Nurjhan, G Perrielo, G Dailey and JE Gerich. (1995). Metabolic effect of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 333:550-554.
47. Vandermolen DT, VS Ratts, WS Evans, DW Stovall, SW Kauma and JE Nestler. (2001). Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75:310-315.
48. Fleming R, ZE Hopkinson, AM Wallace, IA Greer and N Sattar. (2002). Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 87:569-574.
49. Hosono K, H Endo, H Takahashi, M Sugiyama, E Sakai, T Uchiyama, K Suzuki, H Iida, Y Sakamoto, et al. (2010). Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3:1077-1083.
50. Hadad S, T Iwamoto, L Jordan, C Purdie, S Bray, L Baker, G Jellema, S Deharo, DG Hardie, et al. (2011). Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794.
51. Akbar DH. (2003). Effect of metformin and sulfonylurea on C reactive protein level in well-controlled type 2 diabetes with metabolic syndrome. Endocrinology 20:215-218.